Deep Lens has unveiled its new Real Time Feasibility tool that can identify eligible patients and choose the efficient study sites in the Deep Lens Unity Network for cancer clinical trials on a real-time basis.

The offering uses the company’s Cloud-based VIPER software solution, its community cancer sites network and integrated workflows that merge EMR, lab, and genomic information to obtain real-time insights on a specific group of patients.

Trial sponsors and CROs can use the HIPAA-compliant tool to view the number and de-identified sites of existing and future participants who can take part in specific trials.

A clinical research organisation focusing on innovative treatments, Precision for Medicine, has adopted the offering.

The company will employ the solution of Deep Lens to aid its sponsors to quickly detect study sites and patients well-matched for their cancer trials.

Rather than depending on historical data, Real Time Feasibility identifies eligible patients for trials now and those who could be eligible in the future.

Deep Lens president and co-founder Simon Arkell said: “This new dashboard-based subscription offering provides any oncology-focused biopharma company or CRO the ability to quickly and easily view real-time patient counts across our fast-growing network to assess a study’s fit with any study.

“From there, it immediately deploys a trial enrollment project via the Unity Network, if appropriate.

“The use of AI enables scalable data analysis, and any new partner can be set up with real-time insights across our entire network in a matter of hours.”

This October, Southern Oncology Specialists and Deep Lens entered an agreement to use the latter’s AI-based technology and other services to expand the trial offering for patients.